You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

March 2, 2020

Regulation and Planned Taxation of Sodium in Thailand

Informed Counsel

Non-communicable diseases (NCDs) mainly consist of cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, and are the most frequent causes of death worldwide. A 2018 World Health Organization (WHO) fact sheet on NCDs notes that 41 million people die annually from NCDs (71% of global deaths), including 15 million people who die before the age of 70.

Of the total deaths in Thailand every year, 60% are from NCDs, principally hypertension, cardiovascular diseases, kidney disease, and so on. Many of these deaths are caused by unhygienic food intake, not exercising, smoking, or drinking, which are public health problems that the WHO and the Thai government are working to resolve and prevent.

Research conducted by the Kidney Foundation of Thailand found that of the 7 million patients with kidney disease found at an early stage, most could be treated by prescribing medication and recommending changes in eating habits to reduce salt intake, thus preventing kidney disease from increasing in severity. In the adult group, up to 17% were found to have early-stage kidney disease but did not know about it or did not experience symptoms of the disease. If patients in such cases do not see a doctor or undergo health checkups regularly, the symptoms will deteriorate until kidney failure. Because people have two kidneys, if one kidney has any problems, with a 50% loss of function, the patients will not exhibit symptoms as the healthier kidney can still perform waste disposal and blood filtering functions as normal. If the problem continues unabated until a 70% loss of function is reached, the patient will begin to exhibit symptoms of kidney failure, which requires dialysis.

The WHO was relatively early to recognize the importance of solving this problem. An awareness campaign advised the public of the danger of the consumption of high-sodium foods leading to various diseases later on, and the WHO is aiming to reduce hypertension worldwide. The WHO requested the cooperation of member countries, asking them to participate in this targeted campaign and encourage local populations to consume no more than five grams of salt per person per day, or no more than 2,000 mg of sodium, in order to reduce the prevalence of chronic diseases. They also set out strategies for the following actions to reduce sodium intake in the population.

  • Product reformulation
  • Consumer awareness and education campaigns
  • Environmental changes

Finland was the first country to start reducing salt consumption in 1978. The country issued regulations requiring warnings to be displayed on the labels of products that have a high sodium content, together with communicating to consumers, by any media, the dangers of high sodium intake, and promoting the use of reduced-sodium salt for cooking. This policy has been successful. The Finnish population reduced its average daily sodium intake from 5,600 mg per capita in 1970 to 3,200 mg in 2002.

The United Kingdom has used the strategy of affixing easy-to-understand nutrition labels to food products with the cooperation of producers in the food industry. This initiative is controlled by the Food Standards Agency, which set up the Consensus Action on Salt and Health (CASH) project. The UK population reduced its average daily sodium intake from 3,800 mg per capita in 2004 to 3,400 mg in 2008.   

The United States government has long supported the campaign to reduce sodium, going back to 1980. However, the U.S. population has not changed its salt consumption habits.

Other countries (e.g., Australia, Canada, France, Japan, Malaysia, Singapore, and South Korea) also have campaigns to reduce salt intake in their populations.
t the meeting of the Codex Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU) No. 31 in Germany in November 2009, the committee agreed that sodium should be the first nutrient to be limited in its Nutrient Reference Value, which is 2,000 mg following the WHO recommendation.    

For Thailand’s part, Thai government agencies have agreed to cooperate in solving this global issue. Along with campaigns for Thais to realize the importance of the ingredients they take in when consuming food, there are mobilization efforts for the private sector to turn its attention to food so that consumers get less sodium in their daily diets. There has also been an increase in radio, television, billboard, and online advertising about the benefits of limiting sodium consumption. In addition, the government has encouraged public health personnel at all levels to advise the public about reducing their sodium intake, and in October 2018, the Thai FDA changed the Thai recommended daily intake (Thai RDI) of sodium from 2,400 mg to 2,000 mg, following WHO and CCNFSDU recommendations.   

The Department of Disease Control of the Ministry of Public Health launched “SALTS,” its strategy for reducing salt and sodium consumption in Thailand (2016–2025), in October 2016. It comprises the following initiatives:

S:    Stakeholder network. Establishing, developing, and expanding partnerships.

A:    Awareness. Increasing knowledge, awareness and skills among the public, communities, producers/entrepreneurs, relevant professional personnel, and policy makers.

L:    Legislation and environmental reform. Environmental changes for the production and improvement of current products until low-sodium options increase in the market and the public has access to food with low-sodium content.

T:    Technology and innovation. Research and knowledge development, leading to the implementation of practical solutions.

S:    Surveillance, monitoring, and evaluation. Development of surveillance, monitoring, and evaluation systems, focusing on the entire process, output, and results.
   
In April 2016, the Thai Food and Drug Administration (Thai FDA) issued regulations regarding required nutrition labeling and guideline daily amounts (GDA), including GDA labeling for bakery products, biscuits, chocolates, cookies, popcorn, semi-processed foods, snacks, and wafers (e.g., instant noodles, boiled rice, and congee). A GDA-compliant label is an easy-to-read nutrition label displaying the GDA of the ingredients. It contains information about energy, sodium, sugar, and fat values of the entire product and the serving recommendation for daily intake. Also in 2016, the Thai FDA created a “healthier choice” logo to provide a quick visual image to assist consumers in decision-making for more balanced nutrition. Product manufacturers and importers that wish to affix the logo to a product must seek permission to do so from the Nutrition Promotion Foundation under the Institute of Nutrition of Mahidol University, which assesses nutritional values carefully in determining whether to grant permission.    

With the cooperation of several government agencies (e.g., the Thai FDA, Consumer Protection Board Office, Department of Disease Control, Department of Health, and others) and private parties (e.g., Thai Health Promotion Foundation, Federation of Thai Industries, Kidney Foundation of Thailand, Foundation for Consumers, and others) the Less Salt Network campaign was created to reduce sodium consumption in Thailand by setting targets for reducing salt intake by one, two, and three grams by 2016, 2019, and 2022, respectively. By 2025, the campaign aims for people to consume not more than seven grams of salt per person per day, or no more than 2,000 mg of sodium per day.   

The Less Salt Network and related parties have made a strong effort to persuade food companies in Thailand to reduce salt and sodium additives in food, and several food companies are following the campaign and have agreed to reformulate their products. However, many companies are not yet on board and refuse to cooperate. Therefore, the government’s voluntary sodium-reduction target, expected to be implemented by the food industry, has not yet been achieved. The government will continue to explore other strategies for salt reduction in Thailand.   

Salt is not the only culprit that contributes to NCDs. Sugar must also take a portion of the blame, especially in respect of diabetes and obesity. To combat this, Thailand launched a sugar tax on October 1, 2019, as a strategy to reduce people’s sugar intake, which many consider to be the likely model for the future imposition of a similar salt tax. Studies of the impact of a salt tax in Hungary show that such measures can be effective at changing consumers’ eating habits. According to the WHO data, in Hungary, the introduction of a tax on certain foods with very high salt content caused people to turn to less salty food that is not subject to the salt tax.    

The Thai government is thus aiming to set up a salt tax in the coming years. The priority target product is instant noodles, and other products will be included in future phases. However, such a tax is just one available tool, and even after it comes into effect, government agencies and other private parties will still need to find other ways to influence consumers into eating healthier alternatives and to support sustainable consumption habits.  

RELATED INSIGHTS​ 

August 8, 2024
Tilleke & Gibbins has contributed the Thailand chapter to the 2024 edition of Pharmaceutical Advertising from the International Comparative Legal Guides (ICLG) series published by Global Legal Group. This detailed guide offers an in-depth examination of pharmaceutical advertising laws and regulations in multiple jurisdictions around the globe. Each chapter of the guide, structured in a Q&A format, is organized into comprehensive sections covering various aspects of pharmaceutical advertising, including: General rules and codes of practice governing pharmaceutical advertising Required arrangements for ensuring compliance with advertising regulations Procedures for obtaining advertising approvals from regulatory authorities Penalties for non-compliance with advertising rules Guidelines for providing information prior to product authorization Requirements for advertisements directed at healthcare professionals Restrictions on the content of pharmaceutical advertisements The complete Thailand chapter is available as a PDF below. The Thailand chapter—and the full Pharmaceutical Advertising guide—are also freely available on the ICLG website.
July 31, 2024
On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025. Contents of Circular 12 The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements. Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation. Transitional Provisions Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning. Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission. From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.
June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU